Assessing real-world natural history of indolent systemic mastocytosis: A retrospective matched cohort study.

Thanai Pongdee¹, Dakota Powell², Taylor Weis², Robyn Scherber^2,3, Teresa Green², Allison Smither⁴, Purushotham Krishnappa⁵, Katherine Carlson⁴, Prerna Singh⁴, Steve Duff⁶, Erin Sullivan²

¹Division of Allergic Diseases, Mayo Clinic, Rochester, Minn.

²Blueprint Medicines Corporation, Cambridge, Mass.

³Department of Hematology/Oncology, University of Texas Health San Antonio, San Antonio, Tex.

⁴nference, Inc, Cambridge, Mass.

⁵nference, Inc, Bengaluru, India.

⁶Veritas Health Economics Consulting, Kamas, Utah.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Indolent systemic mastocytosis (ISM) is the most common form of systemic mastocytosis, accounting for more than 80% of cases. Patients with ISM experience severe, unpredictable symptoms, including potentially life-threatening anaphylaxis. As a chronic condition, understanding its longitudinal natural history is essential. OBJECTIVE: We sought to evaluate the real-world disease burden…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.